Nov 09,2023

Sword Health and Employer Direct Healthcare Partner to Offer Unique, Integrated Experience for Musculoskeletal Pain Care

Employer Direct Healthcare (EDH), whose SurgeryPlus solution is a high performance specialty network for surgical care nationwide, and Sword Health are announcing an integrated partnership that will deliver a complete solution to musculoskeletal care. As part of this partnership, Sword is introducing a solution specifically to support cancer patients during and after treatment, which is exclusively launching with EDH. The new Sword solution will focus on recovering mobility and strength, aiming to improve function and quality of life, and alleviate psychological distress for those patients. Clients will be able to purchase the integrated solution on a single contract, or add services to any existing contract with a simple order form, including both EDH’s surgery and cancer solutions and Sword’s full range of products, including Digital Physical Therapy, the cancer-centric program, Bloom (women’s pelvic health), Move, Academy, Predict and On-Call.

COLLABORATION PARTNERSHIP

#product & service

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023 TOP STORY

Lunit gets FDA approval for AI cancer diagnosis solution

South Korean medical AI company Lunit announced that its Lunit Insight DBT, an AI imaging diagnosis solution aiding in breast cancer diagnosis, has secured 510(k) pre-market clearance from the US Food and Drug Administration (FDA). This marks Lunit's third FDA approval, joining its AI emergency triage solution Lunit Insight Triage, and the breast imaging analysis tool Lunit Insight MMG. The Lunit InsighT DBT analyses 3D images from digital breast tomosynthesis (DBT) with AI, offering faster and more accurate results than traditional 2D mammography. With FDA approval, Lunit hopes to secure a share of the US market, which represents 65% of global breast cancer screenings, with DBT's widespread adoption.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 10,2023 TOP STORY

Bayer pledges up to $1.5bn for Recursion oncology alliance

Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cancer via a revised deal that could be worth up to $1.5 billion. The two companies will now work on up to seven precision oncology projects, making use of Recursion’s drug discovery platform that draws on a dataset of five trillion biological and chemical relationships and combines wet-lab biology and chemistry with machine learning tools in a form of “digitised” drug discovery. Under the terms of the new agreement, Bayer gets the option to exclusively license novel therapeutics derived from the programme. Juergen Eckhardt, the German group’s business development head, said it “could be one of the most disruptive technologies of our time.” Recursion’s platform has attracted other big pharma clients, notably Roche/Genentech, which signed up for a decade-long partnership in 2021 focusing on neuroscience and oncology drugs that involved a $150 million upfront payment and could be worth several billion dollars if fully exercised. That alliance recently generated its first ‘hit series’ for an undisclosed oncology target.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Nov 09,2023 TOP STORY

Sword Health and Employer Direct Healthcare Partner to Offer Unique, Integrated Experience for Musculoskeletal Pain Care

Employer Direct Healthcare (EDH), whose SurgeryPlus solution is a high performance specialty network for surgical care nationwide, and Sword Health are announcing an integrated partnership that will deliver a complete solution to musculoskeletal care. As part of this partnership, Sword is introducing a solution specifically to support cancer patients during and after treatment, which is exclusively launching with EDH. The new Sword solution will focus on recovering mobility and strength, aiming to improve function and quality of life, and alleviate psychological distress for those patients. Clients will be able to purchase the integrated solution on a single contract, or add services to any existing contract with a simple order form, including both EDH’s surgery and cancer solutions and Sword’s full range of products, including Digital Physical Therapy, the cancer-centric program, Bloom (women’s pelvic health), Move, Academy, Predict and On-Call.

COLLABORATION PARTNERSHIP

#product & service

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023 TOP STORY

Huma signs partnership with Merck KGaA, Darmstadt, Germany to support cancer care

Huma Therapeutics and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment. The Cross-Indication Disease Management Platform will be made available to patients being treated with Merck KGaA, Darmstadt, Germany's cancer therapies. Besides increasing the patients' understanding of their condition, the collaboration will also focus on increasing treatment adherence, facilitating care team and patient communication, delivering educational content, and supporting communication between caregivers and patients. Set for initial launch in 2024, the preliminary direct-to-patient solution will support urothelial carcinoma patients in the UK.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 06,2023

Major study validates Owkin’s best in class AI diagnostic for colorectal cancer biomarker aimed at optimizing patient access to immunotherapy

In a peer-reviewed study published today, a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit™ CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing the precision of diagnosis and treatment of colorectal cancer (CRC). Microsatellite Instability (MSI) is a key genomic biomarker in colorectal cancer and represents ~15% of the overall CRC population. Those patients whose tumors show MSI, are considered likely to respond to immune checkpoint inhibitor therapy and recommended for it. Conversely, immune checkpoint inhibitor is not routinely recommended for those with tumors that are microsatellite stable (MSS). Prescreening tools that can remove the need to test all patients offer the opportunity to streamline the process and reduce pressure on laboratory staff and resources. Owkin's study published in Nature Communications reveals that MSIntuit CRC can accurately rule out nearly 50% of MSS patients, while correctly classifying more than 96% of MSI patients, on par with current gold standard methods (92-95%). Such new solutions pave the way for an optimized screening workflow to screen more patients, faster.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 08,2023

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb. The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease models in specific cancer disease areas. “By combining the power of Tempus’ multimodal data, biological modeling, and machine learning approaches with Bristol Myers Squibb’s discovery expertise and research and development capabilities, we can accelerate discoveries, innovate therapies, and improve the lives of patients battling cancer.” said Ryan Fukushima, Chief Operating Officer at Tempus. The Tempus and Bristol Myers Squibb teams will focus their initial research on identifying new drug targets to expand options for patients lacking effective therapies, or who have become refractory to existing treatment.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Nov 08,2023

Further Group Collaborates with Massive Bio, Integrating Health Solutions for the Insurance Industry to Boost Access to Cancer Clinical Trials Globally

Further Group, a leading global provider of turnkey serious illness solutions for the insurance industry with the objective of breaking down barriers to access cutting-edge medical treatments, is delighted to announce a new partnership with Massive Bio, a pioneer in leveraging artificial intelligence to enhance clinical trial matching for cancer patients. Further Group’s 360, holistic approach to cancer care includes the identification of relevant clinical trials and support with enrolment. They will work closely with Massive Bio to enhance access to cancer clinical trials, streamlining the triage process and ensuring smooth patient admission to treatments that may represent the greatest hope for those facing the disease.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023

Huma signs partnership with Merck KGaA, Darmstadt, Germany to support cancer care

Huma Therapeutics and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment. The Cross-Indication Disease Management Platform will be made available to patients being treated with Merck KGaA, Darmstadt, Germany's cancer therapies. Besides increasing the patients' understanding of their condition, the collaboration will also focus on increasing treatment adherence, facilitating care team and patient communication, delivering educational content, and supporting communication between caregivers and patients. Set for initial launch in 2024, the preliminary direct-to-patient solution will support urothelial carcinoma patients in the UK.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 06,2023 TOP STORY

XtalPi and CK Life Sciences Ink Agreement to Develop Cancer Molecular Diagnostic Models using AI and Biomarker Data

XtalPi, a leading global technology company combining artificial intelligence (AI) and robotics to drive the discovery of novel medicine and innovative materials, announced the signing of a new agreement with CK Life Sciences, a member of the CK Hutchison Group. Expanding upon their existing partnership, the two companies will combine AI algorithms with anonymized clinical and biomarker data from cancer patients and healthy individuals in CK Life Sciences' data repository to jointly explore and develop miRNA-based postoperative molecular diagnostic models for prognostic risk prediction. With the help of AI and machine learning models, this collaborative engagement is hoping to lead to the development of more advanced and intelligent solutions for the processing and modeling of holistic multidimensional biomedical data, biomarker discovery, and postoperative recurrence risk prediction.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY